Andreas Neubauer
#154,057
Most Influential Person Now
Researcher
Andreas Neubauer's AcademicInfluence.com Rankings
Andreas Neubauercomputer-science Degrees
Computer Science
#8325
World Rank
#8752
Historical Rank
Computational Linguistics
#1831
World Rank
#1850
Historical Rank
Machine Learning
#3382
World Rank
#3423
Historical Rank
Artificial Intelligence
#3680
World Rank
#3733
Historical Rank
Download Badge
Computer Science
Andreas Neubauer's Degrees
- PhD Computer Science University of Vienna
- Masters Computer Science University of Vienna
- Bachelors Computer Science University of Vienna
Similar Degrees You Can Earn
Why Is Andreas Neubauer Influential?
(Suggest an Edit or Addition)Andreas Neubauer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. (2002) (1721)
- Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection (1995) (993)
- axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase (1991) (728)
- Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa (2005) (592)
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. (2019) (585)
- Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. (2007) (490)
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey (2015) (423)
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) (2012) (401)
- T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. (2001) (390)
- Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study (2017) (355)
- Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. (1997) (316)
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. (2015) (314)
- Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. (1997) (307)
- Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. (2013) (299)
- Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. (2000) (294)
- Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection (1999) (273)
- Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. (2009) (271)
- Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. (2005) (270)
- Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (2014) (269)
- Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. (2003) (264)
- Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. (2011) (262)
- Helicobacter and gastric MALT lymphoma (2002) (247)
- Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. (2012) (229)
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses (2012) (224)
- Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers (2001) (222)
- Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma (1999) (221)
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). (2020) (219)
- Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development (2005) (216)
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV (2015) (213)
- Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib (2010) (210)
- Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells (2007) (204)
- Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017) (189)
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (187)
- Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. (2001) (187)
- Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia (2005) (183)
- Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. (2001) (183)
- Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. (2010) (168)
- Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series (2007) (167)
- Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. (2006) (165)
- Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. (1994) (158)
- Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia (1994) (156)
- Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. (1991) (144)
- Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. (2008) (139)
- Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia (2003) (131)
- Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C (2003) (130)
- Lack of Interferon Consensus Sequence Binding Protein (ICSBP) Transcripts in Human Myeloid Leukemias (1998) (130)
- Colonic mucosal proliferation is related to serum deoxycholic acid levels (1999) (124)
- Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib (2014) (123)
- Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. (1998) (122)
- New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 (2021) (118)
- Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. (2001) (117)
- Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. (2010) (114)
- Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. (2002) (113)
- Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) (1999) (113)
- Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. (1996) (112)
- Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. (2004) (111)
- Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. (1998) (110)
- New-onset IgG autoantibodies in hospitalized patients with COVID-19 (2021) (110)
- Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial (2019) (109)
- Alterations of the P53 gene are associated with the progression of a human prostate carcinoma. (1992) (109)
- Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. (2000) (108)
- What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT lymphoma? (1997) (106)
- Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial (2018) (103)
- Analysis of gene amplification in archival tissue by differential polymerase chain reaction. (1992) (97)
- Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. (2001) (91)
- Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. (2012) (90)
- Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib (2014) (89)
- Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin (2000) (87)
- Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. (2001) (87)
- ras oncogene activation and occupational exposures in acute myeloid leukemia. (1992) (85)
- siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts (2006) (81)
- Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. (1994) (77)
- PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation (2017) (75)
- Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL). (2004) (75)
- Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. (2003) (71)
- Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. (2013) (71)
- Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori. (2000) (70)
- Mutations in ras proto‐oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia (2001) (70)
- Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. (1996) (70)
- Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. (1993) (68)
- Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. (2001) (67)
- Polymerase chain reaction based assay to detect allelic loss in human DNA: loss of β-interleron gene in chronic myelogeneous leukemia (1990) (66)
- High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. (2013) (66)
- Eradication of Helicobacter pylori and stability of remissions in low-grade gastric B-cell lymphomas of the mucosa-associated lymphoid tissue: results of an ongoing multicenter trial. (2000) (65)
- Karyotype complexity and prognosis in acute myeloid leukemia (2016) (63)
- Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia (1989) (63)
- Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. (1998) (62)
- Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. (2005) (62)
- Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene (1998) (61)
- High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. (2009) (61)
- Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. (1995) (61)
- Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma. (1998) (60)
- Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication (2005) (60)
- Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. (2012) (60)
- Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. (2003) (58)
- Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? (2020) (58)
- Activation of the RAS Pathway Is Predictive for a Chemosensitive Phenotype of Acute Myelogenous Leukemia Blasts (2005) (58)
- Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia (1996) (57)
- Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV (2013) (57)
- Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation (1997) (56)
- High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study (2017) (56)
- Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. (2017) (56)
- Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial (2014) (55)
- Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia (2015) (55)
- Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients (2002) (54)
- Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia (2006) (54)
- Distinct gene expression profile of human mesenchymal stem cells in comparison to skin fibroblasts employing cDNA microarray analysis of 9600 genes. (2005) (53)
- Mutations of the ras proto-oncogenes in childhood monosomy 7. (1991) (52)
- Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue (2005) (52)
- Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma? (1997) (52)
- Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. (2018) (51)
- Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (2006) (51)
- Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). (2001) (50)
- Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction. (1992) (49)
- A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. (2007) (48)
- Treatment with ozone/oxygen‐pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas (2008) (48)
- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML (2017) (48)
- Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial (2010) (48)
- Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia (2016) (47)
- Interferon Regulatory Factor-8 Is Indispensable for the Expression of Promyelocytic Leukemia and the Formation of Nuclear Bodies in Myeloid Cells* (2007) (47)
- Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG‐HD2 trial (2016) (46)
- Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. (2000) (46)
- Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. (1994) (46)
- Treatment of HNSCC cell lines with the EGFR‐specific inhibitor cetuximab (Erbitux®) results in paradox phosphorylation of tyrosine 1173 in the receptor (2006) (45)
- Clonal relationship in multifocal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue (MALT) (2004) (44)
- miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. (2011) (42)
- Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (2016) (42)
- Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. (2004) (41)
- Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions (2000) (41)
- Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). (1996) (39)
- Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region (2005) (39)
- Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells. (2002) (37)
- MicroRNA29a regulates the expression of the nuclear oncogene Ski. (2011) (37)
- NFATc1 as a therapeutic target in FLT3-ITD-positive AML (2015) (37)
- Facilitated detection of oncogene mutations from exfoliated tissue material by a PNA‐mediated ‘enriched PCR’ protocol (2000) (37)
- S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL (2019) (36)
- Gastric MALT lymphoma and its relationship to Helicobacter pylori infection: Management and pathogenesis of the disease (2000) (36)
- CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. (2021) (36)
- Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. (1989) (35)
- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML (2018) (35)
- Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. (2019) (34)
- Gastric MALT‐lymphoma and Helicobacter pylori infection (1997) (33)
- Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV. (2009) (32)
- B-cell Monoclonality Is Associated With Lymphoid Follicles in Gastritis (2003) (32)
- Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial (2014) (32)
- Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study (2015) (32)
- The status of p53 in the metastatic progression of colorectal cancer. (1997) (31)
- Interferon a and T-cell responses in chronic myeloid leukemia (2005) (31)
- The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial (2008) (31)
- Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid (2017) (31)
- Immunosuppressive capabilities of mesenchymal stromal cells are maintained under hypoxic growth conditions and after gamma irradiation. (2015) (30)
- Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. (2002) (30)
- Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. (1999) (30)
- Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing (2018) (30)
- Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy (2009) (29)
- Altered expression of the retinoblastoma susceptibility gene in chronic lymphocytic leukaemia (1993) (28)
- Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 (2016) (28)
- FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. (2006) (28)
- Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: Results of a 196-patient series (2006) (28)
- Bacterial contamination of ex vivo processed PBPC products under clean room conditions (2003) (28)
- A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53mut exhibits ATP-binding cassette transporter upregulation and high glutathione levels (2014) (28)
- Cloning of an interferon regulatory factor 2 isoform with different regulatory ability. (2000) (28)
- Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. (1994) (27)
- Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV (2018) (27)
- CD82 (KAI1), a member of the tetraspan family, is expressed on early haemopoietic progenitor cells and up‐regulated in distinct human leukaemias (1999) (27)
- Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (2019) (26)
- Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. (1997) (26)
- Expression of bomapin, a novel human serpin, in normal/malignant hematopoiesis and in the monocytic cell lines THP-1 and AML-193. (1998) (25)
- Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial (2022) (25)
- High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (25)
- Long-term follow-up of gastric malt lymphoma after H. pylori eradication (2001) (25)
- Expression profiling reveals specific gene expression signatures in gastric MALT lymphomas (2008) (25)
- Simple and Rapid Detection of Factor V Leiden by Allele-specific PCR Amplification (1996) (24)
- Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML (1998) (24)
- Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial (2021) (24)
- Rearrangements of T-cell receptor delta, gamma and beta genes in acute myeloid leukemia coexpressing T-lymphoid features. (1992) (23)
- The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial (2017) (23)
- Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias (1999) (23)
- Comparison of RNA yield from small cell populations sorted by flow cytometry applying different isolation procedures (2007) (23)
- Helicobacter pylori associated gastric B cell MALT lymphoma: predictive factors for regression (2001) (22)
- Abstract CT184: Gilteritinib significantly prolongs overall survival in patients withFLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial (2019) (22)
- Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis (2014) (21)
- Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. (1993) (21)
- Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. (2006) (21)
- Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia (2013) (21)
- Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. (2003) (20)
- P53 and induction of apoptosis as a target for anticancer therapy. (1996) (20)
- Discordant results of flow cytometric ZAP‐70 expression status in B‐CLL samples if different gating strategies are applied (2006) (20)
- Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. (2017) (20)
- Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. (2017) (19)
- MONOCLONAL ANTIBODY Ki‐67 AS A PROLIFERATION MARKER (1987) (19)
- Detection of DNA methylation in the calcitonin gene in human leukemias using differential polymerase chain reaction. (1995) (19)
- Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS) (2020) (18)
- Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). (2005) (18)
- Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV (2018) (18)
- Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. (2019) (17)
- Interferon alpha and T-cell responses in chronic myeloid leukemia. (2005) (17)
- Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. (2019) (17)
- Determination of CD43 and CD200 surface expression improves accuracy of B‐cell lymphoma immunophenotyping (2020) (16)
- A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples. (1999) (16)
- Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients (2016) (16)
- Erfahrungsgeschichten durch Story Telling - eine multifunktionale Wissensmanagement-Methode (2000) (16)
- Genotypic relatedness of yeast isolates from women infected with human immunodeficiency virus and their children (1999) (15)
- EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia (2020) (15)
- Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial (2012) (15)
- Regulation and possible function of axl expression in immature human mast cells (1998) (15)
- Case report: Allergic reaction with immune hemolytic anemia resulting from chlorambucil (1989) (15)
- Receptor activator of nuclear factor‐κB ligand and osteoprotegerin (15)
- Polymerase chain reaction based assay to detect allelic loss in human DNA: loss of beta-interferon gene in chronic myelogenous leukemia. (1990) (15)
- [Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option]. (2010) (14)
- Inhibition of Retinoic Acid Receptor Signaling by SKI in Acute Myeloid Leukemia. (2004) (14)
- Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. (2018) (14)
- Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial (2021) (14)
- Addition of Rituximab to First-Line MCP (Mitoxantrone, Chlorambucil, Prednisolone) Chemotherapy Prolongs Survival in Advanced Follicular Lymphoma - 4 Year Follow-Up Results of a Phase III Trial of the East German Study Group Hematology and Oncology (OSHO#39). (2006) (14)
- Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia (2017) (14)
- Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV, (2011) (14)
- Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV (2011) (13)
- Clinical management of massive retroperitoneal hemorrhage after bone marrow biopsy (2009) (13)
- Spreading of acute myeloid leukemia cells by trafficking along the peripheral outflow pathway of cerebrospinal fluid. (2011) (13)
- Clinical presentation, diagnosis and treatment of Helicobacter pylori -related gastric lymphoma (1996) (13)
- Long-term treatment with rituximab is feasible in selected patients with B-CLL: Response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy (2007) (13)
- Etiology and therapy of Helicobacter pylori-associated gastric lymphomas (2003) (13)
- Molecular alterations in a patient with Turcot's syndrome. (1993) (13)
- Binding of mitogenic plant lectins to human lymphocytes. Flow cytometric analysis. (1989) (12)
- Immune checkpoint inhibitor-associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: A new entity of drug-induced autoimmune encephalitis? (2017) (12)
- The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS) (2021) (12)
- RADIOTHERAPY TO BULKY DISEASE PET‐NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL (2017) (12)
- Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. (1997) (12)
- A flow cytometric assay for the determination of cell proliferation with a monoclonal antibody directed against DNA‐methyltransferase (1989) (12)
- Combined cistrome and transcriptome analysis of SKI in AML cells identifies SKI as a co-repressor for RUNX1 (2018) (12)
- Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial (2015) (11)
- α4 integrin levels on mobilized peripheral blood stem cells predict rapidity of engraftment in patients receiving autologous stem cell transplantation. (2011) (11)
- The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC (2020) (11)
- Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia. (2009) (11)
- [Contrast enhanced sonographic patterns of hepatic candidiasis]. (2010) (11)
- Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. (2021) (11)
- Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. (2017) (10)
- An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. (2017) (10)
- Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AML (2019) (10)
- Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy. (2004) (10)
- Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib (2016) (10)
- Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied (1998) (10)
- Value of herpes simplex virus type-specific serology: a case report. (2012) (10)
- Cure of Helicobacter pylori infection in 125 patients with primary gastric low-grade MALT lymphoma (1998) (10)
- Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation (2010) (9)
- β-Catenin signaling: no relevance in Hodgkin lymphoma? (2012) (9)
- High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion (2018) (9)
- Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study (2021) (9)
- [The role of abdominal ultrasound in hematological diseases]. (2018) (9)
- A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing (2016) (9)
- [Ultrasound in oncology, current perspectives]. (2017) (9)
- Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio. (2019) (9)
- Favorable radiation field decrease in gastric marginal zone lymphoma (2019) (9)
- Einfluß der Lagerung von Pappel, Birke, Eiche und Lärche sowie des Zusatzes von SiO2-Feinstaub auf die Biegefestigkeit zementgebundener Spanplatten (1987) (9)
- Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia (2008) (9)
- Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. (2002) (9)
- Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment (2020) (8)
- IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells (2021) (8)
- The German competence network ‘Acute and chronic leukemias’ (2004) (8)
- Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis (2005) (8)
- Multimodal Therapy for Vertebral Involvement of Systemic Mastocytosis (2009) (8)
- Interim Results of a Phase I/II Clinical Trial of Belinostat in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy. (2008) (8)
- The chronic myelocytic cell line K 562 contains minor (m) as well as major (M) ber/abl fusion mRNAs. (1993) (8)
- A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT Lymphoma (2016) (8)
- Anforderungen, Entscheidungsfreiräume und Stress im Studium (2019) (8)
- Pathologic Hepatic Contrast-Enhanced Ultrasound Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation. (2020) (8)
- Molecular diagnostics in low-grade gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type after Helicobacter pylori eradication therapy. (2001) (8)
- Acute myeloid leukemia with myelodysplasia related changes (2018) (8)
- Detection of Human Herpesvirus-8 and Epstein-Barr Virus DNA in Primary Intraocular Lymphomas (1999) (8)
- Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi- Center Trial AML2003. (2008) (7)
- ACUTE LEUKAEMIA WITH B‐ AND T‐LYMPHOID AND MYELOID CHARACTERISTICS IN A PATIENT WITH A MYELODYSPLASTIC SYNDROME (1989) (7)
- Ras point mutations occur in acute myeloid leukemia with illegitimate T-cell receptor delta gene rearrangement. (1994) (7)
- Secondary Malignancies in CML Patients – Data From the German CML Study IV (2012) (7)
- A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia. (2016) (7)
- Masked inv(3)(q21q26) in a patient with minimally differentiated acute myeloid leukemia. (2001) (7)
- The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML). (2012) (7)
- PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia (1992) (7)
- Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (7)
- Fluorescence in situ hybridization for the BCR/ABL rearrangement is dependent on the percentage of nonlymphocytic cells in peripheral blood stem cell harvests. (1998) (7)
- Detection of minimal acute myeloid leukemia cells in bone marrow by probing for mutated ras oncogenes using the polymerase chain reaction. (1990) (7)
- Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid (2008) (7)
- [Molecular epidemiology of Candida infections in HIV-infected mothers and their offspring]. (1997) (6)
- Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis (2021) (6)
- Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up. (2020) (6)
- Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation (2015) (6)
- Alterations of the retinoblastoma a susceptibility gene in chronic lymphocytic leukemia. (1995) (6)
- Gastrointestinal tract lymphomas (2008) (6)
- Pulmonary Fibrosis in a Patient Treated with Erlotinib (2006) (6)
- Comorbidity, Measured By The Charlson Index, Has No Negative Impact On Remission In Patients With Chronic Myeloid Leukemia: Results Of The Randomized CML-Study IV (2013) (6)
- Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. (2018) (6)
- Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy. (2010) (6)
- Das sonographische Bild des Littoralzellangioms: Fallbericht und Literaturzusammenstellung (2001) (6)
- Complete remission of gastric high-grade B-cell malt lymphoma after cure of helicobacter pylori infection (2000) (6)
- Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis (2021) (6)
- Sonografie in der Onkologie, eine Bestandsaufnahme (2017) (6)
- Response: too much BCR-ABL to live on, but too little BCR-ABL to die on? (2012) (6)
- Clonality analyses in gastric MALT (mucosa-associated lymphoid tissue). (2006) (6)
- Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia. (1999) (6)
- Helicobacter pylori eradication therapy in gastric high grade Hon Hodgkin's lymphoma (NHL) (2001) (6)
- Encephalopathy in a patient after long-term treatment with thalidomide. (2006) (5)
- Cost Evaluation of Rituximab Plus MCP vs. MCP Alone in Advanced Stage Indolent Non-Hodgkin’s-Lymphoma Based on a Randomized Controlled Multicenter Trial. (2004) (5)
- Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation (2015) (5)
- An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission (2011) (5)
- Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS) (1993) (5)
- Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma (2015) (5)
- Are lymphocytic monoclonality and immunoglobulin heavy chain (IgH) rearrangement premalignant conditions in chronic gastritis? (2001) (5)
- Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations (2022) (5)
- DKK1 in multiple myeloma. (2004) (5)
- Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020) (5)
- Quantification of the essential methyl-group donor S-adenosyl-methionine in human colorectal mucosa of patients with inflammatory bowel disease (IBD) and colorectal adenomas (1995) (5)
- Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV (2012) (5)
- Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker (2013) (5)
- Increased Sensitivity of Myeloid Leukemia Cell Lines: Potential of Lovastatin as Bone-Marrow-Purging Agent (2001) (5)
- Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia (2021) (5)
- Efflux of the Tyrosine Kinase Inhibitors Imatinib and Nilotinib (AMN107) Is Mediated by ABCB1 (MDR1)-Type P-Glycoprotein. (2006) (5)
- [AFP-producing adenocarcinoma of the stomach : A rare tumor with poor prognosis]. (2003) (5)
- Early and long-term results of Helicobacter pylori cure of MALT lymphoma — what are the pitfalls (1998) (4)
- Sustained Molecular Responses with Interferon α2a Maintenance Therapy after Imatinib Plus IFN Induction Treatment for Chronic Phase Chronic Myelogenous Leukemia. (2007) (4)
- [Functional hyposplenia after allogenic bone marrow transplantation: a case report]. (2001) (4)
- Potential of autologous immunologic effector cells for prediction of progression of disease in patients with chronic myelogenous leukemia. (1998) (4)
- CD11c+ dendritic cells mediate antigen‐specific suppression in extracorporeal photopheresis (2020) (4)
- Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections. (2022) (4)
- Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT (2020) (4)
- [Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca]. (2007) (4)
- Cytostatic drug testing in human leukemias by means of multiparametric flow cytometry (1987) (4)
- [Sonographic patterns of littoral cell angioma: case report and review of the literature]. (2001) (4)
- Interferon Alpha 2a (IFN) Maintenance Therapy After Imatinib Plus IFN Induction Therapy in Chronic Myeloid Leukemia (CML) Induces Stable Long-Term Molecular Remissions and Is Associated with Increased Proteinase 3 (PR3) Expression and the Presence of PR1-Specific T-Cells. (2009) (4)
- Monitoring of ATG therapy by flow cytometry: comparison of one single-platform and two different dual-platform methods. (2001) (4)
- Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial (2018) (4)
- [Frequency, pattern and differential diagnosis of echogenic splenic changes: sonographic follow-up study]. (2000) (4)
- [Fatal bleeding complications caused by Evans syndrome (autoimmune thrombocytopenia and hemolytic anemia) and type II autoimmune hepatitis in a 56-year-old patient]. (2002) (4)
- Adverse Events (AE) Under Imatinib Treatment Over 10 Years: Results From 1501 Patients Of The Randomized CML-Study IV (2013) (4)
- Value and Diagnostic Accuracy of Ultrasound‐Guided Full Core Needle Biopsy in the Diagnosis of Lymphadenopathy: A Retrospective Evaluation of 793 Cases (2020) (4)
- Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients (2015) (4)
- Phase lb Trial of Pentoxifylline and Ciprofloxacin in Patients Treated with Interleukin-2 and Lymphokine-activated Killer Cell Therapy for Metastatic Renal Cell Carcinoma' (2006) (3)
- THE EXPRESSION OF THE TRANSFERRIN‐RECEPTOR PARALLELS THE STATE OF PROLIFERATION IN HL‐60 CELLS (1989) (3)
- Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells (2022) (3)
- Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial (2019) (3)
- High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels (2019) (3)
- A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma. (2004) (3)
- MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia (2018) (3)
- B-mode ultrasound and contrast-enhanced ultrasound pattern of focal extramedullary hematopoiesis of the spleen in a patient with myeloproliferative disease. (2009) (3)
- Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment (2011) (3)
- Renaissance of Radiotherapy in Intestinal Lymphoma? 10‐Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow‐up of Two German Multicenter Consecutive Prospective Phase II Trials (2020) (3)
- Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. (2017) (3)
- Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV (2014) (3)
- Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial (2020) (3)
- Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial. (2021) (3)
- Flow-cytometric determination of intracellular pH, esterase activity and cell volume in human leukemic cell lines following in vitro incubation with cytostatic drugs. (1989) (3)
- Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission (2021) (3)
- IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity (2022) (3)
- Band 18, Heft 1, März 2002 (2002) (3)
- Primäre Behandlung der Haarzelleukämie mit niedrigdosiertem humanem rekombinantem Interferon-Alpha-2c (Hr-IFn Alpha 2c) im Vergleich zur Therapie nach Splenektomie (1987) (3)
- Nebenwirkungen der medikamentösen Tumortherapie (2011) (3)
- 10-year follow up of 120 patients with gastric MALT lymphoma after Helicobacter pylori eradication--Histological residual disease and second cancers (2008) (3)
- Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy (2017) (3)
- Fertigung und Eigenschaften von schnell abbindenden, zementgebundenen Spanplatten, hergestellt durch Begasung mit Kohlendioxid (1993) (3)
- Lack of Point Mutations in Exons 11–23 of the Retinoblastoma Susceptibility Gene RB-1 in Liver Metastases of Colorectal Carcinoma (2000) (3)
- Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study (2005) (3)
- Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy. (2009) (3)
- Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients (2003) (3)
- Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial. (2004) (2)
- Fatale Blutungskomplikation durch Evans-Syndrom (autoimmune Thrombozytopenie und hämolytische Anämie) und Autoimmunhepatitis Typ II bei einer 56-jährigen Patientin (2002) (2)
- Effect of dose-optimized imatinib (IM) 800 mg on deep molecular responses (CMR 4.5) and prediction of survival: Results from the randomized CML-study IV. (2013) (2)
- Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. (1996) (2)
- management and outcome of Cml-blast crisis: Results from the randomized Cml study Iv : V907 (2014) (2)
- Bedeutung der Helicobacter-pylori-Infektion für die Pathogenese und Therapie von MALT-Lymphomen des Magens (2002) (2)
- Multizentrische prospektive risikoadaptierte Studie zur Therapie von Non-Hodgkin-Lymphomen hoher Malignität (1988) (2)
- [Focal echogenic splenic involvement in malignant lymphoma: a diagnostic problem]. (2000) (2)
- Allgemeine und spezielle Anämiediagnostik (2006) (2)
- Allele-specific PCR amplification of factor V Leiden to identify patients at risk for thromboembolism. (1997) (2)
- Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation (2010) (2)
- Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT (2022) (2)
- Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study (2021) (2)
- Molekulare Tumortherapie (2015) (2)
- Induction Therapy for AML with 90 Mg/m² Daunorubicin Results in Higher Troponin T Serum Levels in Comparison to Treatment with 60 Mg/m² Daunorubicin (2017) (2)
- Funktion und Aufgabe eines interdisziplinären Tumorzentrums - Notwendigkeit eines „Cancer Centers“ für multimodale Therapiekonzepte - (2002) (2)
- Evidence of cross-reactivity of 'carcinoma-specific' KC4 monoclonal antibody with activated mesothelial cells and phytohemagglutinin-stimulated lymphocytes. (1988) (2)
- Seltene Erkrankungen am Blutbild erkennen (2018) (2)
- EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) (2)
- Immuntherapie von Tumorerkrankungen mit Checkpoint-Inhibitoren (2017) (2)
- Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
- Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status (2021) (2)
- Komplikationen der allogenen Knochenmark- und Stammzelltransplantation (2014) (2)
- Konsequenzen des deutschen Antikorruptionsgesetzes für die Drittmittelförderung an Universitätskliniken (2002) (2)
- Interferon α für die Therapie der HCL (1988) (2)
- Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV (2011) (2)
- Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board (2022) (2)
- Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors (2021) (2)
- ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV (2017) (2)
- Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV (2012) (2)
- Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) (2)
- [Prospective comparison of the diagnostic value of cytology and immunocytology in pleural effusion studied by thoracoscopy and biopsy]. (1987) (2)
- [Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma]. (2017) (2)
- Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia (2011) (2)
- Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method (2022) (1)
- MiRNA Expression Signatures in Acute Myeloid Leukemia Are Predictors for Patient Outcome. (2006) (1)
- Helicobacter heilmanii infection and primary gastric low-grade malt lymphoma — A Case Report (1995) (1)
- Sorafenib bei rezidivierter und therapierefraktärer FLT 3-ITD-positiver akuter myeloischer Leukämie : eine neue Behandlungsoption Sorafenib in relapsed and refractory FLT 3-ITD positive acute myeloid leukemia : a novel treatment option (2010) (1)
- Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon α2a (Pegasys®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study. (2007) (1)
- Assessment of Early Therapy Response of Non‐Hodgkin's and Hodgkin's Lymphoma Using B‐Mode Ultrasound and Dynamic Contrast‐Enhanced Ultrasound (2021) (1)
- BCR-ABL-Induced Transcriptional Repression of the Interferon Regulatory Factor 8 (IRF-8/ICSBP) Leads to Depletion of Plasmocytoid Dendritic Cells (PDC), Which May Contribute to Leukemogenesis in a Murine Model of Chronic Myeloid Leukemia (2012) (1)
- Defining Therapy Goals for Major Molecular Remission in Chronic Myeloid Leukemia: Results of the Randomized CML-Study IV (2014) (1)
- [Potential of ultrasound in allogeneic stem cell transplantation and transplant-related complications]. (2021) (1)
- Many questions left open. (2015) (1)
- HIGH SENSITIVITY AND SPECIFICITY OF A COAGULATION ASSAY FOR THE DETECTION OF HETEROZYGOUS AND HOMOZYGOUS FACTOR V LEIDEN-BASED RESISTANCE TO ACTIVATED PROTEIN C (1996) (1)
- Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS) (2021) (1)
- Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL) (2014) (1)
- Analysis of Chimerism in the Early Posttransplantation Period in Cellular Subsets of Patients Undergoing Myeloablative and Non-Myeloablative (Metakine) Allogeneic Blood Stem Cell Transplantation (BSCT) (2001) (1)
- Determination of soluble interleukin-2 receptors after bone marrow transplantation. (1990) (1)
- Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD (2022) (1)
- Diffuse pneumatosis due to central venous catheterization in a patient with acute graft-versus-host disease (2007) (1)
- Dysgranulopoiesis in patients with coronavirus disease 2019 (2021) (1)
- Biologie und Klinik der MALT-Lymphome (1997) (1)
- Adaptive Filter auf der Basis genetischer Algorithmen (1997) (1)
- Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation (2019) (1)
- RESPIRATORY BURST ACTIVITY IN MDS MPS PATIENTS (1994) (1)
- Aberrant CD3-Positive, CD8-Low, CD7-Negative Lymphocytes May Appear During Viral Infections and Mimic Peripheral T-Cell Lymphoma (2020) (1)
- Herstellung von Blutstammzellprodukten unter Reinraumbedingungen der Klasse A mit Hintergrundbedingungen der Klasse B Teil 2 (2002) (1)
- ANTI‐INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY‐ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL UNDERGOING R‐CHOP IMMUNOCHEMOTHERAPY (2017) (1)
- [Effect of the method on the results of determining T-cell subpopulations]. (1989) (1)
- Prospektiver Vergleich der diagnostischen Wertigkeit von Zytologie und Immunzytologie bei thorakoskopisch-bioptisch untersuchten Pleuraergüssen (1987) (1)
- 10-year survival with imatinib: final evaluation of randomized CML-study (2017) (1)
- Klug-entscheiden-Empfehlungen in der Hämatologie und Onkologie (2017) (1)
- Genome Sequencing in Myeloid Cancers. (2021) (1)
- 2.3.3 Magnetische Streuflussprüfung mit angepassten GMR Sensor Arrays (2012) (1)
- Up-Regulation of Heme Oxygenase-1 Is Induced by the Leukemia Stroma-Cell Interaction and Rescues Acute Myeloid Leukaemia (AML) Cells From Cytarabin Induced Cell Death (2012) (1)
- Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) (1)
- Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (2020) (1)
- Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV, (2011) (1)
- Dr. House: Was wir von Hollywood lernen können (2019) (1)
- Stellenwert der Abdomensonografie in der Hämatologie (2018) (1)
- Chronische myeloische Leukämie (2011) (1)
- TNM-Klassifikation maligner Tumoren: Neue Auflage 1987 (1987) (1)
- Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemia (2019) (1)
- Intensified double induction therapy with high dose mitoxantrone , etoposide , m-amsacrine and high dose araC for patients aged 61-65 years with acute myeloid leukemia (1)
- Nuclear NFATc1 Causes Development of Fms-like Receptor Tyrosine Kinase 3 Receptor (FLT3) Internal Tandem Duplication Mutation-Positive (FLT3-ITD) Acute Myeloid Leukemia (AML) and Mediates Drug Resistance (2016) (1)
- [Prevention of stomach carcinoma by Helicobacter pylori eradication. Invitation to participate in the PRISMA Study]. (1999) (1)
- Transfection of receptor tyrosine kinase axl into human haematopoietic cells does not cause spontaneous cellular aggregation (2000) (1)
- Vom Molekül zur Therapie (2011) (1)
- Randomized comparison of 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia : Results from the SAL-DaunoDouble trial (2018) (1)
- S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG (2022) (1)
- Expression of the B-Cell Stimulatory Factors BAFF and APRIL in Gastric MALT Lymphomas. (2009) (0)
- Tandem high dose chemotherapy (THDC) in patients (pts) with small cell lung cancer (SCLC) (2000) (0)
- Unrelated Hematopoietic Blood Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML) in First Remission. (2006) (0)
- Lymphocytosis of large granular lymphocytes associated with anemia and neutropenia: Proof of monoclonality of the LGL-population, but benign clinical course (1989) (0)
- Contents Vol. 59, 2000 (2000) (0)
- Mutation-based, short-term “neoadjuvant” treatment allows resectability in stage IVB and C anaplastic thyroid cancer (2023) (0)
- High age and high frequency of treatment switch in CML patients outside of clinical trials: interim results of the German CML VI trial (2017) (0)
- Rituximab induces a flare-up of activated neutrophil extracellular traps under in vitro conditions (2022) (0)
- Flow-cytometric measurement of colonic mucosal proliferation in endoscopic biopsy specimens (1995) (0)
- Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial (2020) (0)
- [Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results]. (1988) (0)
- The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA (2022) (0)
- Comprehensive Risk Factor Analysis in 939 Adults with Acute Myeloid Leukemia Receiving Risk Stratified Post-Remission Therapy: Results of the Prospective Randomized AML96 Trial of the German Study Initiative Leukemia (DSIL). (2007) (0)
- Transcripts in Human Myeloid Leukemias Lack of Interferon Consensus Sequence Binding Protein (ICSBP) (2013) (0)
- [AFP-producing adenocarcinoma of the stomach. A rare tumor with poor prognosis]. (2003) (0)
- Molekulare Grundlagen der malignen Transformation (2015) (0)
- Modellierung und Validierung ionischer Regulationsprozesse in Nervenzellen mittels X-Kern-Magnetresonanztomographie (2015) (0)
- Molekulare Onkologie (2015) (0)
- Korrespondenzen der DFT (2012) (0)
- SpringerReference Innere Medizin (2015) (0)
- Genetische Veränderungen bei malignen Tumorerkrankungen des Menschen : Kreibsleiden : Aktuelle Diagnostik und Therapie (1997) (0)
- Einfluss von Thrombin und Thrombinrezeptor-aktivierenden Peptiden (TRAP) auf die Mitogenese von Gefäßmuskelzellen: Untersuchungen zur Signaltransduktion (2002) (0)
- Reply to S. Fuji. (2021) (0)
- Erkennung von pulmonaler Graft-versus-Host-Krankheit (GvHD) in allogen stammzelltransplantierten Patienten durch elektronische Nase und Ionenmobilitätsspektrometer (2015) (0)
- Leitlinien – DMP – zertifizierte Brustzentren: Qualitätsentwicklung in Hessen (2004) (0)
- Konzept einer CAD/CAM-Lösung für die rechnerunterstützte Konstruktion und Fertigung von Prolifierwerkzeugen (1988) (0)
- Die Signaltheorie der irregulären Abtastung (2003) (0)
- Reduction of Chemotherapy in Aggressive Non-Hodgkin's Lymphoma with Favorable Prognosis (2019) (0)
- Die Erhoehung der Verkehrssicherheit durch Praeventivmassnahmen zur Reduktion von Alkohol, Drogen und Medikamenten im Strassenverkehr (2002) (0)
- Selektive Akkumulation plasmazytoider dendritischer Zellen (PDC) in perithyreoidalen Lymphknoten bei Patienten mit einer Autoimmunthyreopathie vom Typ Morbus Basedow: Bedeutung für das Verständnis von Autoimmunvorgängen (2006) (0)
- Wirkungsweisen der antineoplastischen Chemo- und Immuntherapie (2007) (0)
- Achievement Of a MR5.0 Within the Randomized CML-Study IV: Feasibility, Differences Between Treatment Arms, and Prognostic Implications (2013) (0)
- Untersuchungen zur Genauigkeitserhöhung beim Scherschneiden von profilförmigen Werkstücken (1991) (0)
- Einfluß der Methode auf das Ergebnis der Bestimmung von T-Zellsubpopulationen (2008) (0)
- Molekulargenetische Diagnostik in der Hämatologie und Onkologie (2002) (0)
- 1109-133 The role of pericardioscopy and epicardial biopsy in determination of the etiological treatment for chronic pericardial effusions (2004) (0)
- Virtuelle Endoskopie fuer Praeoperative Planung und Training von EndonasalerTranssphenoidaler Hypophysenchirurgie (2005) (0)
- Anwendungen der irregulären Abtastung (2003) (0)
- Therapie der zentroblastisch-zentrozytischen und zentrozytischen Lymphome in fortgeschrittenen Stadien — Ergebnisse der Deutschen Studiengruppe zur Behandlung niedrigmaligner Lymphome (1997) (0)
- Beseitigung von durch einen kanalselektionsfilter verursachten verzerrungen (2001) (0)
- Verfahren und Vorrichtung zur Frequenzschätzung bei der Akquistition eines Spreizcode-Signals (2005) (0)
- 7 Hämatologie und Eisenstoffwechsel (2014) (0)
- Der Stellenwert der Sonografie in der Hämatologie und Onkologie – Eine retrospektive Studie von Sonografie-Zuweisungen in einem universitären Ultraschallzentrum (2021) (0)
- Expression of the CTLA-4 ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in chronic myeloid leukemia (2016) (0)
- Prioritäten deutscher Onkologen. Auswertung der „Klug entscheiden“-Umfrage der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) (2017) (0)
- Eigenschaften der DFT (2012) (0)
- Brustzentrum und DMP: Bilanz einer regionalen Qualitätsentwicklung (2007) (0)
- Kinasen als Ziele molekularer Tumortherapie (2015) (0)
- Ein Ausflug in die Funktionalanalysis (2003) (0)
- Therapieoptionen und Prognose gastrointestinaler Lymphome (2007) (0)
- Signalverarbeitung auf der Basis irregulärer Abtastung (2003) (0)
- Potenzial des Ultraschalls bei allogener Stammzelltransplantation und transplantationsassoziierten Komplikationen (2021) (0)
- Die Plattform „Signaltransduktion, Genomics/Proteomics“ (2004) (0)
- FORMEN VON BLECHHOHLTEILEN MIT WIRKMEDIEN: VERGLEICH DER VERFAHRENSVARIANTEN (1998) (0)
- Kyphoplasty for vertebral involvement of systemic mastocytosis (2009) (0)
- Association between helicobacter pylori infection and gastric MALT lymphoma (2001) (0)
- Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia. (2023) (0)
- Was hält der Onkologe davon? – Ausblick (2015) (0)
- FREQUENT USAGE OF SPECIFIC IMMUNOGLOBULIN VH SEGMENTS IN GASTRIC LOW-GRADE B-CELL LYMPHOMAS OF MALT.: 116 (1997) (0)
- Comparison of Immunological and Molecular Markers When Using Interleukin-2 (IL-2) Alone or in Combination with γ-Interferon (IFN-γ) in the Maintenance Therapy of Acute Myeloid Leukemia (AML) (1996) (0)
- High sensitivity and specificity of a coagulation assay for the detection of heterozygous and homozygous factor V Leiden--based resistance to activated protein C. (1996) (0)
- Helicobacter pylori eradication in gastric MALT lymphoma: Results of 316 patients treated inside and outside of a clinical trial. (2006) (0)
- The 10.000/μl Morning Trigger for Prophylactic Platelet Transfusion is Safe: Prospective Experience in 411 AML Patients (2001) (0)
- Main Session I (2002) (0)
- 106P Ultra low-coverage whole genome sequencing for precision oncology in solid tumors (2022) (0)
- Repression of retinoic acid receptor signaling by Ski in prognostically unfavorable forms of acute myeloid leukemia (2004) (0)
- Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome (2023) (0)
- Hematopoietic Stem Cells Actively Extrude Imatinib-Mesylate Due to High ABCG2-Transporter Activity. (2005) (0)
- A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing (2016) (0)
- Efficient generation and characterization of tumor cell subclones with different adhesion pathways involved in cell lysis. (1993) (0)
- Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome (2022) (0)
- Peripheral T‐cell lymphoma immunophenotype in a patient with a history of Muromonab‐CD3 therapy: A case report and a diagnostic dilemma (2021) (0)
- CML Study IV of CML: long-term observation of 1151 patients from the randomized Impact of additional cytogenetic aberrations at diagnosis on prognosis (2012) (0)
- Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) (0)
- Identification of the Oncogene SKI As a New Target Gene of the Myeloid Transcription Factor c-MYB in AML (2016) (0)
- Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide (2022) (0)
- Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML). (2017) (0)
- PF251 GILTERITINIB PROLONGS SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML WHO HAVE COMMON AML CO-MUTATIONS OR A HIGH FLT3-ITD ALLELIC RATIO (2019) (0)
- Virtuelle Endoskopie für Präoperative Planung und Training von Endonasaler Transsphenoidaler Hypophysenchirurgie (2006) (0)
- A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis (2022) (0)
- hematopoietic stem cell transplantation in acute myeloid leukemia Conditioning with 8 Gy total body irradiation and fludarabine for allogeneic (2013) (0)
- Pros and Cons Session: Indications for Allogeneic Transplants in Chronic Leukemias (2002) (0)
- Analysis of paclitaxel-based high-dose chemotherapy (Tax HD-VIP) in 18 patients (pts) with relapsed germ-cell tumors (GCT) (2008) (0)
- Immunochemotherapy (R-MCP) Is Not Superior to Chemotherapy (MCP) Alone in Advanced Mantle Cell Lymphoma - 42 Months Follow Up Results of the OSHO 39 Study. (2007) (0)
- Real World Data on Decitabine Treatment in 296 Patients with Acute Myeloid Leukemia: Outcome and Impact of TP53 Mutations (2017) (0)
- Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 (2021) (0)
- A 15 2 A : H . pylori infection leading to cancer 2 A : 01 REMISSION OF PRIMARY GASTRIC MALT LYMPHOMA AFTER CURE OF HELICOBACTER PYLORI INFECTION : A TWO-YEAR FOLLOW-UP REPORT OF THE GERMAN MALT LYMPHOMA TRIAL (2006) (0)
- Detection of allelic loss within the β1-interferon gene in childhood acute lymphoblastic leukemia using differential PCR (1994) (0)
- Nicht-invasiver Nachweis von Aspergillus fumigatus im Atemwegskondensat von Patienten mit neutropenem Fieber (2015) (0)
- The Genes for Tissue Factor F3 and Nuclear Receptor 4A Are Down-Regulated in Early Death Acute Promyelocytic Leukemia Patients (2018) (0)
- Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia (1998) (0)
- with acute myeloid leukemia ) is associated GFI1 ( Growth Factor Independence 1 A variant allele of (2010) (0)
- Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation (2022) (0)
- Marrow Transplantation Infusions for Relapsed Chronic Myeloid Leukemia After Allogeneic Bone Kinetics of the Graft-Versus-Leukemia Response After Donor Leukocyte (1998) (0)
- The Impact Of Balanced and Unbalanced Karyotypes On Prognosis Of CML: From Chronic Phase To Blast Crisis (2013) (0)
- Development of early gastric cancer 4 years after complete remission of Helicobacter pylori-associated gastric low-grade B-cell malt lymphoma (2000) (0)
- Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry. (2022) (0)
- [CEA as a tumor marker on the cell surface and in the exudate. Comparison in thoracoscopy examined pleural effusions]. (1990) (0)
- Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis (2022) (0)
- IRF4 deficiency vulnerates B progeny for leukemogenesis via Jak3 mutations resembling Ph-like B-ALL in humans (2021) (0)
- Die Theorie der Rahmen (2003) (0)
- Aldehyde Dehydrogenase Expression in Primitive Human Hematopoietic Progenitor Cells with Side Population Characteristic and in Samples from Patients with Acute Myeloid Leukemia. (2005) (0)
- ORIGINAL ARTICLE Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia (2006) (0)
- The 3-month velocity of BCR-ABL decline: a tool for predicting deep molecular response in CML patients (2016) (0)
- AKT activation correlates with chemo- and radio-resistance in variant adherent small cell lung cancer cells (2000) (0)
- The Cytogenetic Profile In Lymphoid and Myeloid CML Blast Crisis (2013) (0)
- [An unusual course of low-malignancy non-Hodgkin lymphoma of the stomach]. (1998) (0)
- Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial. (2023) (0)
- Cytotoxic drug testing in human leukemias by multiparametric flow cytometry (1986) (0)
- Immunocytochemical detection of p21ras expression in fresh human leukaemic cells and cell lines (1989) (0)
- Surfactant protein B (SP-B) variation in patients with lung cancer (2000) (0)
- Persisting Chronic Myeloid Leukemia Stem and Progenitor Cells From Patients in Major Molecular Remission Under Imatinib Are Characterized by Low BCR/ABL Expression. (2009) (0)
- Adverse Prognosis in Acute Myeloid Leukemia with Abnormality Abn(3q): Does EVI1 Matter? (2015) (0)
- The Low Expression of Fc-Gamma Receptor III (CD16) and High Expression of Fc-Gamma Receptor I (CD64) on Neutrophil Granulocytes Mark Severe COVID-19 Pneumonia (2022) (0)
- Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial) (2022) (0)
- Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid (2017) (0)
- High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ cell tumors. (2009) (0)
- Knockdown of the Nuclear Oncogene SKI Inhibits Flt3-ITD Induced Signaling in 32D - Flt3-ITD Cells. (2006) (0)
- Depletion of the TP53 Family Member p73 Sensitizes Cancer Cells towards Cytarabine. (2012) (0)
- Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy (2012) (0)
- Primary surgery with adjuvant chemoradiationtherapy in patients (pts) with small cell lung cancer (SCLC) (T1–2, N0, M0) (2000) (0)
- Expression of Phospholipse C Gamma 2 in Diffuse Large B-Cell Lymphomas, (2011) (0)
- Gastric MALT lymphoma (GML) after helicobacter pylori (Hp) eradication: Prognostic value of histological and molecular findings in 120 patients of a prospective multicenter trial (2007) (0)
- Gastric mucosa-associated lymphoid tissue lymphoma: how to attack the T… for two? (2011) (0)
- Interferon- (cid:1) , but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia (2002) (0)
- Comprehensive Genetic Diagnostics of Acute Myeloid Leukemia By Next Generation Sequencing (2016) (0)
- [Choosing wisely recommendations in hematology and oncology]. (2017) (0)
- Demonstration of Interferon-α Receptors in Cultured Cell Lines and in Myeloid Cells from Patients with Acute or Chronic Myeloid Leukemia (1988) (0)
- Outcomes in Patients With FLT3-Mutated R/R AML Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib Versus Salvage Chemotherapy. (2022) (0)
- The Tetraspanin CD82 Defines Erythroid Committment, Regulates Stem- and Progenitor Cell Survival and Mediates Adhesion. (2004) (0)
- Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit (2021) (0)
- A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV (2014) (0)
- Subject Index Vol. 59, 2000 (2000) (0)
- In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response (2014) (0)
- Interferon regulatory factor 4 is not required for induction of chronic myeloid leukaemia-like myeloproliferative disease by Bcr/Abl in mice (2005) (0)
- In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. (2023) (0)
- Long-term experience after cure of Helicobacter pylori infection in low grade gastric MALT lymphomas: A follow-up study on 50 patients. (1997) (0)
- Maintenance of Respiration Capacity Is an Early Predictor of Drug Resistance in Cancer Cells (2014) (0)
- Leitlinienkonformität und regionale Versorgungsqualität: Entwicklung einer Region (2007) (0)
- [Treatment of low malignancy non-Hodgkin lymphomas with recombinant interferon. Current status]. (1989) (0)
- Respiratory burst activity in MDS and MPS patients. (1994) (0)
- Use of p53 as Cancer Cell Target for Gene Therapy (2000) (0)
- Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 (2016) (0)
- Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience (2021) (0)
- miRNA29a Regulates Oncogenic SKI Expression in Acute Myeloid Leukemia (AML). (2009) (0)
- Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia (2023) (0)
- [Priorities of German Oncologists. Results of the "choosing wisely" survey of the German Society of Hematology and Medical Oncology (DGHO)]. (2017) (0)
- In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific? (2018) (0)
- KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP (2023) (0)
- Autoantibodies are highly prevalent in non–SARS-CoV-2 respiratory infections and critical illness (2023) (0)
- Expression of the Nuclear Corepressor Ski Predicts Response to Histone Deacetylase Inhibitor Valproic Acid in Cells of Acute Myeloid Leukemia. (2012) (0)
- P-567 Topotecan/carboplatin 5 days versus topotecan/carboplatin 3 days in patients with metastasic small cell lung cancer (2003) (0)
- Detection of Significantly Increased Frequencies of Proteinase-3 (Myeloblastin) - Specific CD8+ T-Cells in Patients with De Novo Diagnosed Hepatitis C and Infiltration of Liver Tissue with Proteinase 3 Overexpressing Mononuclear Cells. (2004) (0)
- The Pattern Of Cytogenetic Aberrations In CML BC Stratified For Treatment (2013) (0)
- resistance to activated protein C (letter; comment) detection of heterozygous and homozygous factor V Leiden--based High sensitivity and specificity of a coagulation assay for the (2012) (0)
- Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT (2023) (0)
- Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER). (2023) (0)
- Activation of Phospholipase C γ 2 in Lymphoma Cells. (2005) (0)
- Treatment of Centroblastic-Centrocytic and Centrocytic Lymphomas at Advanced Stages — Results of the German Low-Grade Lymphoma Study Group (1998) (0)
- Pathological Hepatic Contrast-Enhanced Ultrasound (CEUS) Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) (2018) (0)
- Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case report. (2023) (0)
- Low-dose human recombinant interferon-α-2c ARG (Hu-rIFN-α) in hairy cell-leukemia (HCL): design, recruitment and first observations in a prospective randomized multicenter trial (1986) (0)
- Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2023) (0)
- myeloid leukemia expression of myeloblastin and a specific T-cell response in chronic , but not the ABL-kinase inhibitor imatinib (STI571), induces α Interferon (2013) (0)
- 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Andreas Neubauer?
Andreas Neubauer is affiliated with the following schools:
